Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals has reported Other Non-Current Liabilities for 15 years, with the latest figure at $21.2 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 22.43% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 22.43% YoY) and the FY2025 annual result came in at $21.6 million, up 26.56% from the prior year.
• Other Non-Current Liabilities slipped to $21.2 million in Q1 2026 per IRWD's latest filing, from $21.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $39.8 million in Q3 2024 and troughed at $5.1 million in Q1 2022.
• A 5-year average of $21.1 million and a median of $21.6 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities soared 478.86% in 2022, then sank 44.14% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $9.8 million in 2022, then soared by 190.96% to $28.4 million in 2023, then sank by 39.8% to $17.1 million in 2024, then gained by 26.56% to $21.6 million in 2025, then dropped by 2.21% to $21.2 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $21.2 million, $21.6 million, and $22.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.